BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-249@pharmaconomics
DTSTAMP:20260707T050515Z
DTSTART;VALUE=DATE:20260530
DTEND;VALUE=DATE:20260531
SUMMARY:SMMT Phase 2 — ivonescimab
DESCRIPTION:Phase 2 trial results for ivonescimab in first-line metastatic NSCLC\, squamous tumors are due May 30\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1599298/000159929826000043/encouraging-globalxphase.htm\n\nTrack it: https://www.pharmaconomics.com/e/249
URL:https://www.pharmaconomics.com/e/249
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:SMMT catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR